Icovamenib offers a distinct beta-cell hypothesis and BMF-650 provides a near-term obesity readout. The valuation is highly sensitive to clinical outcomes and the terms of the next financing. COVALENT-211 has completed enrollment, but the diabetes readouts now fall in 2027. The September offering was withdrawn without proceeds; the Q2 filing continues to flag substantial doubt about going concern.
rNPV uses stylized 2032–34 commercialization, about eight years of monetization, 35–40% operating contribution, 12% discount rate and later-stage development costs netted inside each pre-risk asset PV. The model is directional because registrational plans and final labels are unknown. Financing sensitivity: $30m at $0.85/sh lowers base FV to $1.63; at $1.50/sh raises it to $1.90. Reducing COVALENT-211 probability from 18% to 8% lowers FV to $1.39; increasing BMF-650 probability from 8% to 20% raises it to $2.33. Probability-weighted scenario check (40% × $0.51 + 45% × $1.74 + 15% × $4.48) is $1.66. Not investment advice.
| Component | Assumption | USD/share |
|---|---|---|
| Icovamenib / COVALENT-211 | $350m pre-risk asset PV × 18% approval probability = $63.0m / 101.055m shares | +0.623 |
| Icovamenib / COVALENT-212 | $240m pre-risk asset PV × 15% probability = $36.0m / 101.055m shares; patient overlap excluded | +0.356 |
| Icovamenib / Type 1 diabetes | $120m pre-risk asset PV × 10% probability = $12.0m / 101.055m shares | +0.119 |
| BMF-650 / obesity | $500m pre-risk asset PV × 8% probability = $40.0m / 101.055m shares | +0.396 |
| OPAL combination option | $40m pre-risk asset PV × 5% probability = $2.0m / 101.055m shares; 1.1% of base FV | +0.020 |
| Cash at 2026-06-30 | $35.2m cash including restricted cash / 101.055m shares; balance may have since declined | +0.348 |
| Corporate cash use | $26.0m reserve (about $8.7m × 3 quarters) / 101.055m shares | −0.257 |
| Existing warrant claim | $14.3m June warrant-liability mark / 101.055m shares; no warrant shares in base denominator | −0.142 |
| Financing proceeds | $30m gross at $1.05/sh less $2m fees = $28.0m net / 101.055m shares | +0.277 |
| FV base case | 0.623 + 0.356 + 0.119 + 0.396 + 0.020 + 0.348 − 0.257 − 0.142 + 0.277 = 1.740 | 1.740 |
The June balance sheet had no funded borrowing, but $10.48m current liabilities and a $14.25m non-current warrant liability. 37.024m common warrants were outstanding at a $2.50 exercise price; 23.0m expire 2026-12-20 and 14.024m expire 2028-10-08. The 2025 shelf covers up to $300m of securities and accommodates a $100m ATM; no ATM shares were issued in H1 2026. The 2026-09-23 withdrawal generated no cash. Form 4 review found director option awards in June and no verified insider sale above $500k in the previous 12 months; awards are not open-market purchases.
| Item | FY 2024 | FY 2025 | H1 2026 | FY 2026E | Guidance / status |
|---|---|---|---|---|---|
| Product revenue ($m) | 0 | 0 | 0 | 0 | Pre-commercial |
| R&D expense ($m) | 118.1 | 62.0 | 18.3 | ~37–43 | Analyst run-rate range |
| G&A expense ($m) | 26.0 | 19.3 | 7.3 | ~14–16 | Analyst run-rate range |
| Net loss ($m) | −138.4 | −61.8 | −20.7 | N/M | Warrant mark distorts GAAP line |
| Operating cash use ($m) | 119.9 | 70.4 | 21.7 | ~41–47 | Analyst estimate, not guidance |
| End-period cash ($m) | 58.6 | 56.2 | 35.2 | ~10–15 | Before any new financing |
| Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Revenue ($m) | 0 | 0 | 0 | 0 | 0 |
| Gross margin % | N/M | N/M | N/M | N/M | N/M |
| Net loss ($m) | −20.7 | −16.4 | +4.6 net income* | −12.4 | −8.3 |
| End-of-period cash ($m) | 56.6 | 47.0 | 56.2 | 45.1 | 35.2 |
Business model — menin inhibitor and oral GLP-1 pipeline
Icovamenib / COVALENT-211 Product revenue $0 · rNPV $63m Phase II · fully enrolled Insulin-deficient T2D despite standard treatment. 64 participants at 18 sites, randomized 2:1 to 100mg icovamenib or placebo for 12 weeks, then off-treatment follow-up through Week 52. Week 26 primary data expected Q1 2027. Examine prespecified HbA1c, C-peptide, retention and safety. Icovamenib / COVALENT-212 Product revenue $0 · rNPV $36m Phase II · enrolling T2D inadequately controlled on a GLP-1 regimen. Enrollment expected to complete before end-2026, with Week 26 data in Q2 2027. The study tests a distinct add-on population, but molecule and biology make results correlated with 211. Icovamenib / Type 1 diabetes Product revenue $0 · rNPV $12m Phase II follow-up COVALENT-112 observations showed a 52% mean C-peptide AUC rise at Week 12 in an evaluable early-diagnosis 200mg cohort, then near-baseline preservation at Week 52. The historical comparator was not a concurrent randomized control; prospective confirmation remains necessary. BMF-650 / GLP-131 obesity Product revenue $0 · rNPV $40m Phase I · October readout Oral small-molecule GLP-1 receptor agonist. Four multiple-ascending-dose cohorts were complete by June and a rapid-titration cohort was added. First 28-day human weight-loss data now expected October 2026. Preclinical primate findings cannot establish competitive human efficacy. OPAL / icovamenib + semaglutide Product revenue $0 · rNPV $2m Academic Phase II arm First participant dosed 13 August 2026. Leicester plans 64 participants randomized 1:1 to low-dose semaglutide with or without icovamenib. Week 24 outcomes cover physical function, body composition and metabolic measures; this is exploratory.
In COVALENT-111, management reported up to 1.5 percentage points placebo-adjusted Week 52 HbA1c improvement in a severe insulin-deficient subgroup (p=0.01) and up to 1.8 points in a GLP-1-treated subgroup (p=0.05). These small-subgroup results should not be used as expected effects in 211/212. See the 24 August company update and OPAL release .
Legal, regulatory and risk analysis
SWOT analysis
- +Two distinct metabolic mechanisms create several clinical tests.
- +COVALENT-211 enrolled all 64 participants.
- +H1 operating cash use fell substantially year over year.
- +Prior subgroup findings support a testable diabetes hypothesis.
- −No product revenue or approved therapy.
- −Management disclosed substantial going-concern doubt.
- −Lead value rests on small exploratory subgroups until Phase II.
- −Low share price raises expected per-share financing cost.
- →October BMF-650 readout may establish a human obesity signal.
- →COVALENT-211/212 could validate a beta-cell restoration pathway.
- →Positive data could improve financing or partnership terms.
- →Clinical differentiation could unlock value beyond current market cap.
- !A discounted raise could dilute existing holders materially.
- !Weak efficacy or safety could impair either program.
- !Trial delays may consume cash before pivotal evidence arrives.
- !Better-funded obesity competitors may limit pricing and uptake.
Summary by assessment area
- The menin hypothesis is intriguing but not confirmed in a randomized Phase II readout.
- BMF-650 is the nearer binary test; 211/212 provide deeper diabetes validation in 2027.
- $35.2m June-end cash and roughly $10m Q2 operating use put financing near the center of the thesis.
- Raise price and share count matter more to per-share value than small clinical-model adjustments.
- $1.74 modeled base value versus the $1.26 verified close represents about 38% upside.
- The conditional $0.51-$4.48 range is wide; re-underwrite after clinical data or financing.
Sources and as-of discipline. Price used: BMEA $1.26, regular-session close 29 September 2026 (T-1), cross-checked against Stock Analysis , MarketBeat and ChartExchange ; market cap $91.33m and 52-week range $0.872–$2.99. No unverified 30 September intraday quote is substituted. Primary records: Q2 2026 10-Q , 2025 10-K , Q2 release , 211 update , 22 September 8-K , withdrawn offering , OPAL . Peer values: ALT , GPCR , VKTX . Consensus: Stock Analysis, 24 August 2026 update . This document is for informational purposes only and does not constitute financial or investment advice. Data and estimates may change materially after the next clinical or financing announcement.